Quetiapine in the treatment of acute bipolar mania: Efficacy across a broad range of symptoms

Journal of Affective Disorders

Volumn 100, Issue SUPPL. 1, 2007, Pages

  McIntyre, Roger S ^a   Konarski, Jakub Z ^b   Jones, Martin ^c   Paulsson, Björn ^d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Bipolar disorder; Combined analysis; Efficacy; Mania; Quetiapine; Specificity; Tolerability

Indexed keywords

PLACEBO; QUETIAPINE;

ARTICLE; BIPOLAR MANIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; SYSTEMATIC REVIEW; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 34249307214     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2007.02.007     Document Type: Article

References (31)

1. Akiskal H.S., Bourgeois M.L., Angst J., Post R., Moller H., and Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 59 suppl 1 (2000) S5-S30
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (2000), American Psychiatric Association, Washington, DC
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159 (2002) 1-50
4. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 50 (1998) 143-151
5. Angst F., Stassen H.H., Clayton P.J., and Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J. Affect. Disord. 68 (2002) 167-181
6. Baldessarini R.J., Hennen J., Wilson M., Calabrese J., Chengappa R., Keck Jr. P.E., McElroy S.L., Sachs G., Vieta E., Welge J.A., Yatham L.N., Zarate Jr. C.A., Baker R.W., and Tohen M. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J. Clin. Psychopharmacol. 23 (2003) 370-376
7. Berk M., and Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs 65 (2005) 257-269
8. Bowden C., Grunze H., Mullen J., Brecher M., Paulsson B., Jones M., Vågerö M., and Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 66 (2005) 111-121
9. Buckley P., Paulsson B., and Brecher M. Treatment of agitation and aggression in bipolar mania: Efficacy of Quetiapine. J. Affect. Disord. 100 (2007) S33-S43
10. Frye M.A., Ketter T.A., Leverich G.S., Huggins T., Lantz C., Denicoff K.D., and Post R.M. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J. Clin. Psychiatry 61 (2000) 9-15
11. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 17 (2003) 149-173 (discussion 147)
12. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R.W., Vieta E., and Moller H.J. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: treatment of mania. World J. Biol. Psychiatry 4 (2003) 5-13
13. Judd L.L., and Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 73 (2003) 123-131
14. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., and Keller M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60 (2003) 261-269
15. Judd L.L., Schettler P.J., Akiskal H.S., Maser J., Coryell W., Solomon D., Endicott J., and Keller M. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. J. Neuropsychopharmacol. 6 (2003) 127-137
16. Ketter T.A., Jones M., and Paulsson B. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. J. Affect. Disord. 100 (2007) S45-S53
17. Kupfer D.J., Frank E., Grochocinski V.J., Cluss P.A., Houck P.R., and Stapf D.A. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J. Clin. Psychiatry 63 (2002) 120-125
18. Lindenmayer J.P. The pathophysiology of agitation. J. Clin. Psychiatry 61 Suppl 14 (2000) 5-10
19. McIntyre R.S., and Konarski J.Z. Bipolar disorder: a national health concern. CNS Spectr. 9 11 Suppl 12 (2004) 6-15
20. McIntyre R.S., Konarski J.Z., and Yatham L.N. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum. Psychopharmacol. 19 (2004) 369-386
21. McIntyre R.S., Brecher M., Paulsson B., Huizar K., and Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 15 (2005) 573-585
22. Osby U., Brandt L., Correia N., Ekbom A., and Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58 (2001) 844-850
23. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., and Docherty J.P. The Expert Consensus Guideline Series: medication treatment of bipolar disorder 2000. Postgrad. Med. Special Issue (2000) 1-104 (April)
24. Sachs G., Chengappa K.N.R., Suppes T., Mullen J.A., Brecher M., Devine N.A., and Sweitzer D.E. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 6 (2004) 213-223
25. Suppes T., Webb A., Paul B., Carmody T., Kraemer H., and Rush A.J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am. J. Psychiatry 156 (1999) 1164-1169
26. Sussman N., Mullen J., Paulsson B., and Vagero M. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J. Affect. Disord. 100 (2007) S55-S63 10.1016/j.jad.2007.02.008
27. Vieta E., Calabrese J.R., Hennen J., Colom F., Martinez-Aran A., Sanchez-Moreno J., Yatham L.N., Tohen M., and Baldessarini R.J. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J. Clin. Psychiatry 65 (2004) 1420-1428
28. Vieta E., Mullen J., Brecher M., Paulsson B., and Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 21 (2005) 923-934
29. Vieta E., Goldberg J.F., Mullen J., Vagero M., and Paulsson B. Quetiapine in the treatment of acute mania: Target dose for efficacious treatment. J. Affect. Disord. 100 (2007) S23-S33 10.1016/j.jad.2007.02.009
30. Yatham L.N., Paulsson B., Mullen J., and Vagero A.M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol. 24 (2004) 599-606
31. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S., Macqueen G., McIntyre R., Sharma V., Silverstone P., Alda M., Baruch P., Beaulieu S., Daigneault A., Milev R., Young L.T., Ravindran A., Schaffer A., Connolly M., and Gorman C.P. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 7 Suppl 3 (2005) 5-69